Your donation will make a difference:
Cystic Fibrosis Trust
Forum

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

41-44 of 44 results for all trials

Sort by:

Filter by

Trial status

Inclusion age

FEV1

Trial type

Location

Mutation

Therapeutic category

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis (CF) is a genetic disease caused by mutations in the gene encoding a cell transport protein (ion channel). This ion channel transports chloride ions in and out of cells in multiple organ systems. When ions are not transported correctly the salt and water balance in cells and tissues is not controlled, leading to the production of sticky mucus in the lungs, airways and intestines. Vertex is developing treatments to help increasing production of the ion channel and increase transport of chloride ions. IVA and Orkambi are two drugs that have been approved for treatment. Vertex is also developing TEZ and now VX-440. VX-440 increases the production of the ion channel, but in a different way to the current treatments. So, it is hoped that by using VX-440 as well as current treatments the production of the ion channel will be increased even further. Primary Objectives 1) To evaluate the safety and tolerability of VX-440 in dual and triple combination with tezacaftor (TEZ) and/or ivacaftor (IVA). 2) To evaluate to effectiveness of VX-440 in dual and triple combination with TEZ and/or IVA

Read more Phase II
  • Trial Reference Number

    82171

  • Age

    13 - 17

  • Length of participation

    20 weeks

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function

VX15-809-110 Cystic Fibrosis

This study will look at whether two drugs (called lumacaftor and ivacaftor) can help treat cystic fibrosis when taken together over a long period of time. It will also look at whether they are safe over this period. You can only take part in this study if you took part in a study called VX14-809-109, and if you meet certain criteria. These criteria will be checked by the study doctor and nurse at a screening visit. If you meet these criteria you will be treated with lumacaftor and ivacaftor together for approximately 96 weeks. A follow up visit will be held 28 days after the last dose of lumacaftor and ivacaftor. You will need to attend the clinic for 15 visits over the study duration and will undergo a range of tests. Participants who stopped taking the study drugs early in the VX14-809-109 study will be invited to take part in an observational study. They will not receive the study drug but will receive regular phone calls.

Read more Phase III
  • Trial Reference Number

    50600

  • Age

    0 - 12

  • Length of participation

    96 weeks

  • Trial status

    Open

  • Therapeutic category

    Restore CFTR Function

VX14770116: Ph IV Observational Study for CF Patients

The study is being done to learn more about the effectiveness of Kalydeco in CF patients with the following specific gene mutaions: G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P or G1349D. The study also looks to explore the effect of Kalydeco on your quality of life. This is an observational study. This means that your cystic fibrosis treatment and medical care will not change because you are participating in this study and the sponsor will not pay for Kalydeco. Your doctor will continue to make all decisions regarding your proper treatment and care. No part of this study is experimental.

Read more Phase IV
  • Trial Reference Number

    45686

  • Mutation

    No copies of F508del

  • Age

    0 - 12

  • Length of participation

    48 months

  • Trial status

    Closed

  • Therapeutic category

    Other

Evaluation of the High Frequency Digit Triplet test in Cystic Fibrosis

Cystic Fibrosis (CF) is an inherited condition which affects 9000 people in the UK, over half of whom are adults. Life expectancy is around 40 years but it is increasing steadily, largely due to improved treatment of chronic lung infections. However, treatment over many years with some antibiotics (“aminoglycosides”) may have toxic effects, including permanent and severe hearing loss, usually affecting both ears. Even mild hearing loss has a damaging effect on schooling and future employment prospects. The conventional hearing test - the Pure Tone Audiogram – must be performed by an audiologist using specialised equipment. It is not practical to use this test regularly in CF patients to prevent further hearing loss. We will evaluate a new hearing test - the High Frequency Digit Triplet (HFDT) test. This test mimics how individuals hear in real life situations (such as a noisy room), requires only a computer and does not need clinically trained personnel. We will evaluate the new test in stable patients and in those about to receive intravenous antibiotics for a chest infection. We will also see if it is feasible to do the test in primary school children. If the HFDT test is accurate and practical we will apply for a new research grant which would allow us to see if the test is accurate when performed in the home (where there may be more background noise). We could then offer this test to every CF patient in the UK over 5 years. Patients could perform this test at home and then bring the result to discuss with their doctor if antibiotic treatment is likely. We believe this test could prevent hearing loss in many people with CF and allow substantial savings both in testing and in hearing aid provision (where hearing is irreversibly damaged).

Read more Not Applicable
  • Trial Reference Number

    27261

  • Length of participation

    1 day

  • Trial status

    Open to recruitment

  • Therapeutic category

    Other

41-44 of 44 results for all trials